Novartis Reports 25% Surge in Q3 Profit, Confirms Strong Year-End Outlook

Novartis reported a 25% increase in net income for Q3, driven by strong sales in key prescription medicines, solidifying its positive outlook for the year.

• In the third quarter, Novartis achieved an operating income of $4.5 billion, a 27% rise in constant currencies, reflecting robust sales and reduced impairments.
• The Swiss drugmakers net income surged by 25% compared to the previous year, underscoring its strong market position in the United States dollar-denominated pharmaceutical sector.
• Novartis continues to invest in research and development, which, despite increasing costs, is expected to bolster its portfolio of innovative therapies and generic drugs.